WO2008072591A1 - 鉄代謝改善剤 - Google Patents
鉄代謝改善剤 Download PDFInfo
- Publication number
- WO2008072591A1 WO2008072591A1 PCT/JP2007/073766 JP2007073766W WO2008072591A1 WO 2008072591 A1 WO2008072591 A1 WO 2008072591A1 JP 2007073766 W JP2007073766 W JP 2007073766W WO 2008072591 A1 WO2008072591 A1 WO 2008072591A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- iron
- dialysis
- iron metabolism
- improving agent
- citrate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
Definitions
- the present invention relates to an iron metabolism improving agent for improving iron metabolism in a living body, and in particular, iron in a living body of a chronic renal failure patient who is receiving blood purification therapy such as hemodialysis, hemofiltration and hemofiltration dialysis.
- the present invention relates to an iron metabolism improving agent for improving metabolism.
- the present invention improves in vivo iron metabolism by administering the iron metabolism improving agent to chronic renal failure patients receiving blood purification therapy such as hemodialysis, blood filtration and hemofiltration dialysis.
- the present invention relates to a method for improving in vivo iron metabolism by using a dialysate and / or a replenishment solution for permeation containing the iron metabolism improving agent.
- the present invention relates to a blood purification method including hemodialysis and hemofiltration dialysis by performing blood purification on a chronic renal failure patient using a dialysate containing the iron metabolism improving agent. Further, the present invention relates to a blood purification method including hemodialysis and blood filtration by performing blood purification using a dialysis replenisher containing the iron metabolism improving agent for chronic renal failure patients. is there.
- Renal anemia developed in patients with chronic renal failure due to blood purification therapy is caused by a relative shortage of erythropoietin produced in the kidney tissue due to decreased renal function.
- rHuEPO human genetically modified erythropoietin
- rHuEPO formulation is used.
- Non-patent Document 1 serum iron in hemodialysis patients was lower than that in healthy subjects. Serum ferritin concentration was significantly higher. In these patients, the iron concentration in polynuclear leukocytes increased to about 3 times that of healthy subjects, and at the same time the ferritin concentration increased to about 1.5 times.
- iron transporter protein is involved in intracellular iron metabolism.
- many new findings have been obtained at the cellular level, particularly in the duodenum and reticuloendothelial cells.
- TfR transferrin receptor
- Fe 3+ trivalent iron
- DMT1 Force Hue Mouth Portin 1
- FP1 is also known as a protein that pumps iron out of the cell.
- Non-patent Document 1 The present inventors have also elucidated the relationship between the increase in intracellular iron concentration and the iron transport protein in polynuclear leukocytes.
- FP1 was involved in the uptake of iron into the polynuclear leukocytes.
- TfR an iron uptake protein
- TfR an iron uptake protein
- iron transport protein is expressed in cells throughout the body, it is possible that similar changes in expression observed in polynuclear leukocytes from dialysis patients may also occur in the reticuloendothelial system.
- the most important iron metabolism in the living body is a so-called regenerative system that phagocytoses in an aged erythrocyte reticuloendothelial system, extracts iron from hemoglobin, and reuses iron for hematopoiesis in the bone marrow. This system will reuse approximately 20-25 mg of iron per day.
- CRP C-reactive protein
- Non-patent Document 3 it has been shown that some of EPO-resistant renal anemia is also associated with a chronic inflammatory condition.
- Non-patent Document 4 As a causative agent of iron transport protein dysregulation in dialysis patients, inflammatory site force-in Is attracting attention!
- Non-patent Document 5 The present inventors have studied the influence of these inflammatory site force-ins on iron transport proteins using cultured cells derived from human monocytes. As a result, increased expression of TfR and DMT1 and suppression of FP1 expression were observed at the mRNA and protein levels. In addition, even when iron was preloaded, the same change was observed by site force-in stimulation. In other words, it was suggested that in the reticuloendothelial system, site force-in induces iron transport protein dysregulation that is related to intracellular iron concentration.
- the conventional commercial dialysate contains a small amount (8--12mEq / U of acetic acid for stabilization, and the acetic acid promotes high-site force inemia by stimulating monocytes.
- aconitase a succinic acid converting enzyme
- IRP iron regulatory protein
- IRP 1 force It exists in mRNA of iron transport protein under iron deficiency. It has been reported that inhibition of TfR and DMT1 mRNA degradation and inhibition of translation initiation of FP 1 mRNA occurs (Non-patent Document 6). Since it is known to have ditase activity, citrate increases aconitase activity. May attenuate the binding of IRP1-IRE and correct iron transport protein abnormalities.
- iron transport protein dysregulation similar to that of polynuclear leukocytes is induced in reticuloendothelial cells. It is considered to be the main cause of EPO-resistant renal anemia due to the ⁇ enclosure of iron '' and also plays a central role in the onset and progression of various complications that affect patient prognosis.
- Non-Patent Document 1 Otaki Y, et al .: Am. J. Kidney Dis .: 43, 1030-1039 (2004)
- Non-Patent Document 2 Ali M, et al .: Lancet: 20, 652-655 (1982)
- Non-Patent Document 3 Barany P: Nephrol. Dial. Tranplant.: 16, 224-227 (2001)
- Non-patent document 4 Ludwiczek S, et al .: Blood .: 101, 4148-4154 (2003)
- Non-Patent Literature 5 Nanami M, et al .: Arterioscler Thromb. Vase. Biol .: 25, 2495-2501 (2 005)
- Non-Patent Document 6 Hentze MW et al .: Cell: 117, 285-297 (2004)
- the present invention is an iron metabolism improving agent that improves the in vivo iron metabolism of chronic renal failure patients who are receiving blood purification therapy such as hemodialysis, hemofiltration and hemofiltration dialysis. It is an issue to provide.
- the present invention also provides iron in vivo by administering the iron metabolism improving agent of the present invention to a patient with chronic renal failure who is undergoing blood purification therapy such as hemodialysis, blood filtration, and hemofiltration dialysis. It is intended to provide a method for improving metabolism, and in particular, to provide a method for improving in vivo iron metabolism by using a dialysis solution and / or a dialysis replenisher containing the iron metabolism improving agent. To do.
- the present invention provides a blood purification method including hemodialysis and hemofiltration dialysis by performing blood purification on a chronic renal failure patient using a dialysate containing the iron metabolism improving agent. Furthermore, for patients with chronic renal failure, a blood purification method including hemodialysis and blood filtration by performing blood purification using a dialysis replenisher containing the iron metabolism improving agent is provided. The task is to do.
- the present invention that solves such a problem has the following configuration as an aspect thereof.
- an iron metabolism improving agent characterized by containing citrate and / or citrate
- the present invention provides:
- the iron metabolism improving agent according to any one of (1) to (4) above for patients with chronic renal failure who have undergone blood purification therapy such as hemodialysis, hemofiltration and hemofiltration dialysis! A method for improving iron metabolism in vivo, characterized by administering
- the present invention provides, as another aspect,
- the iron metabolism improving agent provided by the present invention contains citrate and / or kennate. Especially in patients with chronic renal failure who have undergone blood purification therapy with such an iron metabolism improving agent! Has the effect of improving the iron availability reduced by renal failure.
- the iron metabolism improving agent of the present invention restores the iron metabolism regeneration system that recycles iron, and as a result, high-site force inemia is prevented and the regulation of iron transport protein in vivo is prevented. It corrects the normal.
- the iron metabolism-improving agent of the present invention is particularly effective in improving EPO-resistant renal anemia in patients with chronic renal failure, avoiding the risk of complications, and improving the patient's QOL and prognosis. It is excellent.
- the iron metabolism improving agent provided by the present invention contains citrate and / or citrate as described above, and particularly iron metabolism that contains citrate and / or citrate as an electrolyte. It is an improving agent.
- acetic acid and / or acetate as an electrolyte, containing citrate and / or citrate, and further containing other electrolytes and glucose alone or in combination. It is an iron metabolism improving agent.
- the iron metabolism improving agent of the present invention is preferably administered in the form of a dialysate or a replenishment solution for dialysis.
- a dialysis solution or dialysis replenisher is preferably a bicarbonate dialysis solution or a dialysis replenisher containing sodium bicarbonate sodium bicarbonate as an alkalizing agent.
- the iron metabolism improving agent provided by the present invention contains an electrolyte component, a pH adjuster and / or glucose in the dialysate! /, In the form of a so-called “agent A”. In actual administration, it is preferably diluted with diluting water or preferably diluted with a so-called “agent B” consisting of sodium bicarbonate sodium bicarbonate.
- the dialysis replenisher is preferably in the form of a so-called “solution B” containing an electrolyte component, a pH adjuster and / or glucose.
- the electrolyte component, the pH adjuster and the carbonate Used by mixing with the so-called "Liquid A" consisting of sodium hydride used by mixing with the so-called "Liquid A" consisting of sodium hydride
- Other electrolyte components contained in the iron metabolism improving agent of the present invention include citrate and
- citrate such as sodium citrate
- sodium chloride, potassium chloride, magnesium chloride, calcium chloride, sodium lactate, potassium lactate, calcium lactate and the like can be mentioned.
- Particularly preferred electrolyte components are sodium chloride, lithium chloride, calcium chloride, magnesium chloride, and sodium citrate.
- glucose in addition, it further contains glucose, and a pH adjuster that becomes an appropriate pH when prepared as a dialysate and / or a dialysate replenisher.
- pH adjuster examples include citrate, lactic acid, hydrochloric acid, malic acid, ascorbic acid, tartaric acid, sodium hydroxide and the like, and citrate and hydrochloric acid are particularly preferable.
- bicarbonate dialysis solution or bicarbonate replenisher When diluting and mixing to an appropriate concentration, as a bicarbonate dialysis solution or bicarbonate replenisher
- insoluble compounds In the case where calcium ion is included as an electrolyte component contained in the iron metabolism improving agent provided by the present invention, the ability to generate an insoluble compound with citrate and / or citrate, for example, sodium citrate The formation of insoluble compounds can be prevented by adjusting the pH to a low level with an acid.
- the precipitation suppressing effect can be exhibited by using citrate.
- the electrolyte components contained in the so-called dialysate “A” and dialysate replenisher “B” contained in the so-called dialysate “A” and dialysate replenisher “B”
- bicarbonate ions contained in the so-called “B agent” for dialysis fluid and "A fluid” for dialysis replenisher When sodium bicarbonate is mixed, it reacts with calcium bicarbonate ion and magnesium ion to produce an insoluble metal carbonate, so it is prepared as a dialysate for artificial kidney after use, after dilution and mixing. At the same time, there is an advantage that stability is maintained for a long time due to the effect of suppressing precipitation of citrate.
- the amount of citrate and / or citrate used is usually an amount that is adjusted to about pH 2.2 to 2.9 as a preparation.
- the amount adjusted to 0.02 to 5 mEq / L as described above may be contained as ions.
- the iron metabolism improving agent provided by the present invention attenuates the binding of IRP1-IRE through an increase in aconitase activity by the action of citrate and / or citrate contained therein, It becomes possible to correct dysregulation of transport proteins.
- the iron metabolism improving agent of the present invention does not contain acetic acid at all, it is possible to prevent high-site force inemia in dialysis patients and correct iron transport protein dysregulation.
- the release of “iron-enclosure” in the reticuloendothelial system is accompanied by an increase in serum iron concentration, an improvement in iron metabolism abnormalities, and an increase in iron availability, thereby improving EPO-resistant renal properties. This will greatly contribute to the improvement of anemia.
- the iron metabolism improving agent of the present invention is extremely specific.
- the iron metabolism improving agent of the present invention is in the form of a dialysis solution! /, In addition to the form of a dialysis replenisher, and mixed with a pharmaceutically acceptable carrier, excipient, diluent, etc. , Elixir, strength, capsule, granule, pill, transdermal preparation, suspension, emulsion, suppository, powder, spirit, tablet, syrup, injection, patch, limonase, etc. It can also be administered in the form. Alternatively, it can be administered in a form that can be taken orally (fed) using an appropriate excipient, such as powders, granules, tablets, liquids (beverages, jelly drinks, etc.), Can give candy etc.
- a pharmaceutically acceptable carrier such as powders, granules, tablets, liquids (beverages, jelly drinks, etc.), Can give candy etc.
- ni In ⁇ Inu; Hidene ⁇ ⁇ ⁇ ⁇ ⁇ ⁇
- Pentobarbital sodium (3 Omg / kg) was administered into the cephalic vein as an induction anesthesia, and pentobarbital sodium was continuously administered intravenously using an infusion pump to maintain anesthesia during dialysis.
- An 8Fr catheter filled with heparinized physiological saline (10 units / mL) was inserted into the femoral artery and vein and fixed to create a blood access.
- heparinized physiological saline (10 units / mL) was inserted into the femoral artery and vein and fixed to create a blood access.
- tracheostomy was performed and a ventilator was attached to the animal.
- Hemodialysis was performed using a single-use hemodiafiltration device DBG-01 (manufactured by Nikkiso Co., Ltd.).
- DBG-01 manufactured by Nikkiso Co., Ltd.
- PS-0.6 UW and pediatric blood circuit were used, respectively.
- dialysate of the present invention As a test group, the dialysate of the present invention and a commercially available dialysate having the formulation shown in Table 1 below.
- Hemodialysis was performed at a blood flow rate of 100 mL / min and a dialysate flow rate of 300 mL / min, with no water removal and a dialysis time of 4 hours.
- the force remained at the same level as that before dialysis.
- the plasma citrate concentration decreased by dialysis (Fig. 1).
- the comparison between the groups was significantly higher in the dialysate group of the present invention than in the commercially available dialysate group after 2 and 4 hours of dialysis.
- the concentration of acetic acid in plasma is not detected during dialysis in the dialysate group of the present invention. (P ⁇ 0.05, Table 2).
- the dialysis using the dialysate of the present invention may have the effect of improving iron utilization decreased due to renal failure.
- Example 2 Examination of iron metabolism improvement effect by administration of citrate in both nephrectomized rats Using rats from which the kidney had been removed, the effect of iron administration on the iron metabolism was investigated.
- Tests were conducted in the test groups shown in Table 3 below using 8-week-old male CD (SD) rats (body weight of about 300 g). Rats were intoxicated by intraperitoneal administration of sodium pentobarbital (50 mg / kg), and then the kidneys were removed from the back side of the rats (no treatment for group 1 in Table 3), and a central vein catheter (CVC) was placed. Was enforced.
- SD 8-week-old male CD
- CVC central vein catheter
- the collected blood was centrifuged under cooling, and the plasma was measured for creatine (Cre), urea nitrogen (BU N), iron and citrate.
- Plasma citrate was 5.27 ⁇ 1. 23 mg / dL in group 1 16. 38 ⁇ 9. 49 mg / dL in group 2 by bilateral nephrectomy, 17. 11 ⁇ 18. 64 mg in group 3 It increased to / dL ( Figure 6). The difference in plasma citrate concentration before and after administration in Group 3 was 21.08 ⁇ 13. 18 mg / dL, which was increased by administration of citrate. On the other hand, in group 2, the difference decreased slightly to -0 ⁇ 92 ⁇ 2.20 mg / dL.
- the iron in plasma was 112 ⁇ 14; ⁇ / (1 force was 1 in group 1 and 61 ⁇ 17 ⁇ ⁇ / (1 in group 2 was clearly decreased due to renal failure (Fig. 7),
- abnormal iron metabolism S In the 3 groups of citrate administration, the difference in plasma iron concentration before and after administration was higher (14 ⁇ ; 18 ⁇ g / dU) compared to 2 groups (85 ⁇ 17 g / dL) (Fig. 7). It was suggested that the iron concentration in the plasma was improved by the administration of citrate and the iron concentration in the plasma could be improved by improving the amount of iron.
- Example 3 Examination of the iron metabolism improvement effect by the administration of Kung Koji at the time of analysis in bilaterally isolated rats
- Tests were conducted in the test groups shown in Table 4 below using male CD (SD) rats.
- SD male CD
- the rats were anesthetized by intraperitoneal administration of sodium pentovalpital (50 mg / kg), and then the kidneys were removed from the back side of the rats.
- the rats were anesthetized by intraperitoneal administration of pentobarbital sodium (50 mg / kg), and then a catheter was placed in the left femoral artery and left femoral vein to create a blood access, and kenic acid administration and A central venous catheter (CVC) was placed for blood collection.
- CVC central venous catheter
- dialysis was performed for 4 hours under anesthesia using a commercially available dialysate (AK-Solita DU) .Groups 2 and 3 in Table 4 were analyzed during the analysis.
- a physiological saline solution or 4.5 w / v% sodium citrate solution was continuously administered from CVC at a dose rate of 1. OmL / hour, and 1 mL of blood was collected from CVC immediately after completion of dialysis.
- the collected blood was centrifuged under cooling, and the plasma was measured for creatine (Cre), urea nitrogen (BU N), iron and citrate.
- Agent A (10% width sodium chloride 2, 148. Og
- Liquid A (1. Components / amount in OlOmL)
- Liquid B (components / amount in 1, OlOmL)
- the present invention does not contain acetic acid and / or acetate, but contains citrate and / or kenate for patients with chronic renal failure undergoing blood purification therapy.
- citrate and / or kenate for patients with chronic renal failure undergoing blood purification therapy.
- the medical effect is significant in that it can contribute to improvement.
- FIG. 1 shows the results of plasma citrate concentration in Example 1:
- FIG. 2 is a graph showing the results of serum iron concentration in Example 1:
- FIG. 3 is a diagram showing the results of UIBC in Example 1:
- FIG. 4 is a diagram showing the results of TIBC in Example 1:
- FIG. 5 is a diagram showing the results of iron staining of spleen tissue in Example 5 of Example 1.
- FIG. 6 is a graph showing the results of plasma citrate concentration in Example 2:
- FIG. 7 is a graph showing the results of plasma iron concentration in Example 2:
- FIG. 8 is a graph showing the results of plasma citrate concentration in Example 3:
- FIG. 9 is a graph showing the results of plasma iron concentration in Example 3:
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- External Artificial Organs (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008549294A JP5592609B2 (ja) | 2006-12-12 | 2007-12-10 | 鉄代謝改善剤 |
EP07850340.6A EP2123270B2 (en) | 2006-12-12 | 2007-12-10 | Iron metabolism-improving agent |
US12/482,723 US20090306002A1 (en) | 2006-12-12 | 2009-06-11 | Iron metabolism-improving agent |
US13/741,721 US20130131179A1 (en) | 2006-12-12 | 2013-01-15 | Iron metabolism-improving agent |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006334294 | 2006-12-12 | ||
JP2006-334294 | 2006-12-12 | ||
JP2007079488 | 2007-03-26 | ||
JP2007-079488 | 2007-03-26 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/482,723 Continuation US20090306002A1 (en) | 2006-12-12 | 2009-06-11 | Iron metabolism-improving agent |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008072591A1 true WO2008072591A1 (ja) | 2008-06-19 |
Family
ID=39511611
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/073766 WO2008072591A1 (ja) | 2006-12-12 | 2007-12-10 | 鉄代謝改善剤 |
Country Status (7)
Country | Link |
---|---|
US (2) | US20090306002A1 (ja) |
EP (1) | EP2123270B2 (ja) |
JP (2) | JP5592609B2 (ja) |
KR (1) | KR101467957B1 (ja) |
CN (2) | CN105640930A (ja) |
TW (1) | TWI440457B (ja) |
WO (1) | WO2008072591A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016503768A (ja) * | 2012-12-18 | 2016-02-08 | ガンブロ・ルンディア・エービーGambro Lundia Ab | 透析組成物 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI440457B (zh) † | 2006-12-12 | 2014-06-11 | Ajinomoto Kk | 含檸檬酸及/或檸檬酸鹽之組成物的用途 |
JP5752791B2 (ja) | 2010-06-23 | 2015-07-22 | ガンブロ・ルンディア・エービーGambro Lundia Ab | 透析酸前駆組成物 |
US20130189376A1 (en) | 2010-06-23 | 2013-07-25 | Gambro Lundia Ab | Dialysis precursor composition |
KR102001689B1 (ko) | 2011-06-20 | 2019-07-18 | 감브로 룬디아 아베 | 투석 전구 조성물 |
US9821102B2 (en) | 2011-06-20 | 2017-11-21 | Gambro Lundia Ab | Dialysis precursor composition |
ES2684218T3 (es) | 2011-12-21 | 2018-10-01 | Gambro Lundia Ab | Composición precursora de diálisis |
WO2013092284A1 (en) | 2011-12-21 | 2013-06-27 | Gambro Lundia Ab | Dialysis precursor composition |
SE536913C2 (sv) | 2012-03-08 | 2014-10-28 | Gambro Lundia Ab | Komposition för dialys |
MX357998B (es) * | 2015-03-20 | 2018-07-11 | Antonio Hernandez Miramontes Jorge | Una mezcla de acidos carboxilicos, especificamente acido citrico, acido succinico, acido fumarico y acido malico para el tratamiento de pacientes con insuficiencia renal cronica, insuficiencia renal aguda, hepatopatias agudas o cronicas que cursen con hiperamonemia, enfermedades congenitas con alteraciones enzimaticas en el ciclo de la urea, asi como condiciones clínicas que cursen con balance nitrogenado negativo. |
JP7395288B2 (ja) | 2019-08-30 | 2023-12-11 | ポッカサッポロフード&ビバレッジ株式会社 | アンジオテンシンIIType1受容体拮抗剤 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1087478A (ja) * | 1996-09-13 | 1998-04-07 | Tomita Seiyaku Kk | 重炭酸固形透析用剤 |
JP2003104869A (ja) * | 2001-09-28 | 2003-04-09 | Shimizu Pharmaceutical Co Ltd | 透析用剤およびその製造方法 |
WO2006073164A1 (ja) * | 2005-01-07 | 2006-07-13 | Ajinomoto Co., Inc. | 透析用製剤 |
WO2006130065A1 (en) * | 2005-05-30 | 2006-12-07 | Gambro Lundia Ab | Peritoneal dialysis fluid |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5869458A (en) * | 1994-10-14 | 1999-02-09 | Waite; Christopher S. | Frozen rehydration formulation and delivery system therefor |
US5624668A (en) * | 1995-09-29 | 1997-04-29 | Luitpold Pharmaceuticals, Inc. | Iron dextran formulations |
US5906978A (en) † | 1996-08-14 | 1999-05-25 | Hemocleanse, Inc. | Method for iron delivery to a patient by transfer from dialysate |
US6779468B1 (en) † | 1997-08-07 | 2004-08-24 | Ajay Gupta | Method and pharmaceutical composition for iron delivery in hemodialysis and peritoneal dialysis patients |
US7670491B2 (en) † | 1998-10-20 | 2010-03-02 | Advanced Renal Technologies | Buffered compositions for dialysis |
WO2001000204A1 (en) † | 1999-06-30 | 2001-01-04 | Ajay Gupta | Method and pharmaceutical composition for parenteral administration of iron |
WO2001021233A1 (en) * | 1999-09-22 | 2001-03-29 | Advanced Renal Technologies | High citrate dialysate and uses thereof |
US6566402B2 (en) * | 2000-05-24 | 2003-05-20 | Uab Research Foundation | Use of citrate-containing dialysate for renal dialysis treatment |
US6706007B2 (en) * | 2000-12-29 | 2004-03-16 | Chf Solutions, Inc. | Feedback control of ultrafiltration to prevent hypotension |
US20070231395A1 (en) * | 2004-03-30 | 2007-10-04 | Toshiya Kai | Solid Pharmaceutical Preparation for Dialysis |
TWI440457B (zh) † | 2006-12-12 | 2014-06-11 | Ajinomoto Kk | 含檸檬酸及/或檸檬酸鹽之組成物的用途 |
-
2007
- 2007-12-10 TW TW096147002A patent/TWI440457B/zh not_active IP Right Cessation
- 2007-12-10 JP JP2008549294A patent/JP5592609B2/ja active Active
- 2007-12-10 WO PCT/JP2007/073766 patent/WO2008072591A1/ja active Application Filing
- 2007-12-10 CN CN201610085612.4A patent/CN105640930A/zh active Pending
- 2007-12-10 CN CN201510666104.0A patent/CN105380936A/zh active Pending
- 2007-12-10 KR KR1020097014516A patent/KR101467957B1/ko not_active IP Right Cessation
- 2007-12-10 EP EP07850340.6A patent/EP2123270B2/en not_active Not-in-force
-
2009
- 2009-06-11 US US12/482,723 patent/US20090306002A1/en not_active Abandoned
-
2013
- 2013-01-15 US US13/741,721 patent/US20130131179A1/en not_active Abandoned
-
2014
- 2014-06-27 JP JP2014132719A patent/JP2014218504A/ja not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1087478A (ja) * | 1996-09-13 | 1998-04-07 | Tomita Seiyaku Kk | 重炭酸固形透析用剤 |
JP2003104869A (ja) * | 2001-09-28 | 2003-04-09 | Shimizu Pharmaceutical Co Ltd | 透析用剤およびその製造方法 |
WO2006073164A1 (ja) * | 2005-01-07 | 2006-07-13 | Ajinomoto Co., Inc. | 透析用製剤 |
WO2006130065A1 (en) * | 2005-05-30 | 2006-12-07 | Gambro Lundia Ab | Peritoneal dialysis fluid |
Non-Patent Citations (13)
Title |
---|
ALI M ET AL., LANCET, vol. 20, 1982, pages 652 - 655 |
BALOGUN R.A.: "Chronic Kidney Disease: A brief Review for the Primary Care Physician", JCOM, vol. 11, no. 12, December 2004 (2004-12-01), pages 784 - 790, XP008110148 * |
BARANY P, NEPHROL. DIAL. TRANPLANT., vol. 16, 2001, pages 224 - 227 |
FRITZ J.C. ET AL.: "Estimation of the Bioavailability of Iron", JOURNAL OF THE AOAC, vol. 58, no. 5, 1975, pages 902 - 905, XP008110147 * |
HENTZE MW ET AL., CELL, vol. 117, 2004, pages 285 - 297 |
HISANO T. ET AL.: "Citric Acid Kamususan Tosekieki ni yoru Mususan Ketsueki Toseki (AFHD) no Hyoka", DAI 49 KAI ANNUAL MEETING OF THE JAPANESE SOCIETY FOR DIALYSIS THERAPY YOKOSHU, 18 May 2004 (2004-05-18), XP003025816 * |
KATAGIRI T. ET AL.: "Toseki Kanja ni Okeru Citric Acid Naifuku no Rinshoteki Koka ni Tsuite", DAI 48 KAI ANNUAL MEETING OF THE JAPANESE SOCIETY FOR DIALYSIS THERAPY YOKOSHU, 20 May 2003 (2003-05-20), pages 997, XP003025815 * |
LUDWICZEK S ET AL., BLOOD., vol. 101, 2003, pages 4148 - 4154 |
NANAMIM ET AL., ARTERIOSCLER THROMB. VASC. BIOL., vol. 25, 2005, pages 2495 - 2501 |
OTAKI Y ET AL., AM. J. KIDNEY DIS., vol. 43, 2004, pages 1030 - 1039 |
See also references of EP2123270A4 * |
TANAKA M. ET AL.: "Citric Acid Kogyoketsuho ni yoru Ketsueki Toseki", KIDNEY AND DIALYSIS, vol. 18, no. 6, 1985, pages 65(789) - 70(794) * |
YUASA K. ET AL.: "Tetsu Howa Shisu 16% Miman no Ketsueki Toseki Kanja ni Okeru Citric Acid Daiichi Tetsu Natrium no Yukosei no Kento", NIPPON TOSEKI IGAKU KAISHI, vol. 28, no. 9, 1995, pages 1213 - 1217, XP003025814 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016503768A (ja) * | 2012-12-18 | 2016-02-08 | ガンブロ・ルンディア・エービーGambro Lundia Ab | 透析組成物 |
Also Published As
Publication number | Publication date |
---|---|
JP5592609B2 (ja) | 2014-09-17 |
CN105640930A (zh) | 2016-06-08 |
TWI440457B (zh) | 2014-06-11 |
EP2123270A4 (en) | 2010-07-07 |
EP2123270A1 (en) | 2009-11-25 |
EP2123270B2 (en) | 2016-06-15 |
US20090306002A1 (en) | 2009-12-10 |
JPWO2008072591A1 (ja) | 2010-03-25 |
CN105380936A (zh) | 2016-03-09 |
KR101467957B1 (ko) | 2014-12-02 |
EP2123270B1 (en) | 2012-08-29 |
US20130131179A1 (en) | 2013-05-23 |
KR20090100390A (ko) | 2009-09-23 |
JP2014218504A (ja) | 2014-11-20 |
TW200833320A (en) | 2008-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5592609B2 (ja) | 鉄代謝改善剤 | |
US8864699B2 (en) | High citrate dialysate and uses thereof | |
KR101461436B1 (ko) | 골 대사 개선제 | |
JP2009051850A (ja) | L−カルノシンを含む腎不全の処置用の組成物 | |
WO2010112570A1 (en) | Dialysis solution | |
EA002479B1 (ru) | Способ и фармацевтическая композиция для доставки железа у пациентов, получающих гемодиализ и перитонеальный диализ | |
AU2014264537B2 (en) | Dialysis formulation | |
Simon | Detoxification in hemosiderosis | |
CN101568334A (zh) | 铁代谢改善剂 | |
JP6890353B2 (ja) | 分子状水素を含む腎臓疾患の腎機能改善のための組成物 | |
JP6169458B2 (ja) | 鉄代謝改善用輸液剤 | |
JP2015189737A (ja) | 鉄代謝改善輸液剤 | |
Lundby et al. | MO524: Gender Differences in Intravascular Volumes Vanish if Expressed per Lean Body Mass | |
Priyadharshini | A Study of Intradialytic Complications in Patients Undergoing Hemodialysis | |
US20090023806A1 (en) | Aluminum-storage disease improving agent | |
Rajashekar | A study of serum ferritin concentration And transferrin saturation in patients With anemia in chronic kidney disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780045678.X Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07850340 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008549294 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007850340 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020097014516 Country of ref document: KR |